Keywords : HCC
A CROSS SECTIONAL ANALYTICAL STUDY TO EVALUATE THE PREVALENCE AND EARLY DIAGNOSIS OF NAFLD IN VARIOUS COMORBIDITIES USING LIPID PROFILE AND HEPATIC ENZYMES AS BIOMARKERS
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 3058-3066
Background: Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is often asymptomatic and silent, and progresses slowly and is one of the most common causes of chronic liver disease. NAFLD affects a third of the world population with very much high prevalence among patients with diabetes mellitus, obesity, hypertension, dyslipidemia, hypothyroidism etc. The natural history of NAFLD ranges from pure steatosis to steatohepatitis (NASH) to cirrhosis and in some patientsto hepatocellular carcinoma (HCC). NAFLD has been found to be the hepatic components of metabolic syndrome which is one of the leading causes of chronic liver disease. This study aimed to determine the biochemical hepatic markers and lipid profile among NAFLD patients and their possible relationship with degrees of fatty liver and other comorbidities to aid the clinician tointervene early in order to delay the occurrence of complications associated with NAFLD.
Materials and Methods: In this analytical cross sectional study, 145 individuals aged 20–69 years referred to the Govt Medical College/ GGH Hospital Suryapet during the period from June 2021 to May 2022, were included through sequential sampling method after meeting inclusion and exclusion criteria and after taking informed consent and ethical committee approval. Serum lipid profile and Serum liver enzymes was estimated on ERBA EM 360 auto analyzer.
Results: We found significant increase in lipid parameters (TC, LDL-C, VLDL-C, and TG), liver enzymes (AST, ALT, and GGT) and decrease in HDL-C and AST/ALT (Deritis ratio) in NAFLD with type 2 DM compared to controls.
Conclusion: We conclude from our study that in obesity, dyslipidemia, hypertension, hypothyroidism and Type 2 DM the elevated liver enzymes and lipid profile could be biomarkers for the early diagnosis of NAFLD with Type 2 DM and other comorbidities.